Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)

Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18FDG-PET in Obese Person

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01150019

Enrollment

120

Registered

2010-06-24

Start date

2010-04-30

Completion date

2010-06-30

Last updated

2010-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

atherosclerosis, vascular inflammation, resistin, adiponectin, 18FDG-PET

Brief summary

Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis.Resistin was shown to induce vascular endothelial dysfunction and vascular smooth muscle cell proliferation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between circulating resistin and vascular inflammation detected by 18FDG-PET in obese persons.

Interventions

OTHERCross sectional study

This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers for visiting routine medical check in our clinic

Exclusion criteria

* History of cardiovascular disease (myocardial infarction, unstable angina,stroke, or cardiovascular revascularization) * Diabetes * Hypertension * Malignancy * Severe renal or hepatic disease * Subjects taking medications that might affect inflammation such as non-steroidal anti-inflammatory drugs (NSAIDs) and statin

Design outcomes

Primary

Measure	Time frame
Vascular inflammation in carotid arterial wall represented as the target-to-background ratio (TBR) using FDG-PET	12 weeks

Secondary

Measure	Time frame
Circulating serum adiponectin levels	12 weeks
carotid intima-media thickness levels measured using ultrasonography	12 weeks
Circulating serum resistin levels	12 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026